 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology...

Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

Latest Ratings for ACAD
 DateFirmActionFromTo Mar 2022Cantor FitzgeraldMaintainsOverweight Mar 2022Goldman SachsMaintainsNeutral Mar 2022MizuhoMaintainsNeutral
 View More Analyst Ratings for...

Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead...

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m...

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares

A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have lost about 23.4% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?

Expert Ratings For ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD  Free Report)  Equities researchers at Zacks Research lowered their FY2024 earnings estimates for shares of ACADIA Pharmaceuticals in a...

ACADIA Pharmaceuticals Inc. to Post FY2024 Earnings of $0.64 Per Share, Zacks Research Forecasts (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD  Free Report)  Equities research analysts at Zacks Research dropped their Q1 2024 earnings per share (EPS) estimates for shares of ACADIA...

Q1 2024 EPS Estimates for ACADIA Pharmaceuticals Inc. Decreased by Zacks Research (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD  Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 29th, there was short interest...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Significant Growth in Short Interest

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Volume (M)	988,365.00
52-Wk High	$33.99
52-Wk Low	$16.60

ACAD Acadia Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals